American Society of Hirudotherapy

Probing intermolecular backbone H-bonding in serine proteinase-protein inhibitor complexes

Research article published in Chemistry & biology (1999)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Drug DevelopmentLu W et al. · Chemistry & biology, 1999

Abstract

BACKGROUND: Intermolecular backbone H-bonding (N-H.O=C) is a common occurrence at the interface of protein-protein complexes. For instance, the amide NH groups of most residues in the binding loop of eglin c, a potent serine proteinase inhibitor from the leech Hirudo medicinalis, are H-bonded to the carbonyl groups of residues in the target enzyme molecules such as chymotrypsin, elastase and subtilisins. We sought to understand the energetic significance of these highly conserved backbone-backbone H-bonds in the enzyme-inhibitor complexes. RESULTS: We synthesized an array of backbone-engineered ester analogs of eglin c using native chemical ligation to yield five inhibitor proteins each containing a single backbone ester bond from P3 to P2' (i.e. -CONH-to -COO-). The structure at the ligation site (P6-P5) is essentially unaltered as shown by a high-resolution analysis of the subtilisin-BPN'-eglin c complex. The free-energy changes (DeltaDeltaGNH-->O) associated with the binding of ester analogs at P3, P1 and P2' with bovine alpha-chymotrypsin, subtilisin Carlsberg and porcine pancreatic elastase range from 0-4.5 kcal/mol. Most markedly, the NH-->O substitution at P2 not only stabilizes the inhibitor but also enhances binding to the enzymes by as much as 500-fold. CONCLUSIONS: Backbone H-bond contributions are context dependent in the enzyme-eglin c complexes. The interplay of rigidity and adaptability of the binding loop of eglin c seems to play a prominent role in defining the binding action.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, U.S. Gov't, P.H.S.
Indexed MeSH termsAmino Acid SequenceAnimalsCattleChromatography, High Pressure LiquidCrystallography, X-RayHydrogen BondingMacromolecular SubstancesModels, MolecularMolecular Sequence DataProtein BindingProtein ConformationSerine Endopeptidases

Summary

Intermolecular backbone H-bonding (N-H.O=C) is a common occurrence at the interface of protein-protein complexes.

Why This Matters for Hirudotherapy

This study used native chemical ligation to synthesize backbone-engineered ester analogs of eglin c—a potent serine proteinase inhibitor from the leech Hirudo medicinalis—to probe the energetic contributions of intermolecular backbone hydrogen bonds at the enzyme-inhibitor interface. Five ester analogs with single backbone modifications from P3 to P2' were tested against bovine α-chymotrypsin, subtilisin Carlsberg, and porcine pancreatic elastase, revealing context-dependent free-energy changes (0–4.5 kcal/mol) and a remarkable 500-fold binding enhancement from one NH→O substitution at P2. This is directly relevant to ASH's domain as it provides detailed molecular-level insight into the binding mechanism of a leech-derived proteinase inhibitor. The caveat is that this is a purely in vitro structural and biophysical chemistry study with no therapeutic or clinical implications directly addressed; the findings concern basic protein–protein interaction energetics rather than hirudotherapy applications.

Citation

Probing intermolecular backbone H-bonding in serine proteinase-protein inhibitor complexes

Lu W et al. · Chemistry & biology, 1999

Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.